skip to main content

AF-Cardioversion Anticoagulation — ABIM Board MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCardiologyAF-Cardioversion AnticoagulationABIM Board

A 66‑year‑old patient presents with atrial fibrillation of unknown duration and is scheduled for elective electrical cardioversion. Which of the following anticoagulation strategies is recommended prior to cardioversion?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Therapeutic anticoagulation for at least 3 weeks prior to cardioversion, or a transesophageal echocardiography–guided strategy to exclude atrial thrombus

In AF of unknown duration—or ≥48 hours—US guidelines (2014 AHA/ACC/HRS; reaffirmed in 2023 ACC/AHA/ACCP/HRS update) mandate one of two strategies: at least 3 weeks of therapeutic anticoagulation prior to cardioversion (with continuation for ≥4 weeks after) or a TEE-guided approach to exclude left atrial thrombus before earlier cardioversion. Option A is incorrect because the duration is unknown, not necessarily <48 hours. Option C is inadequate—aspirin alone fails to protect against stroke risk. Option D provides only intra-procedural anticoagulation and misses preprocedural protection. Option E is false—paroxysmal AF still carries thromboembolic risk when the onset is uncertain.

Reference: 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, Section 6.1.1 (2014); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, https://pmc.ncbi.nlm.nih.gov/articles/PMC11104284/